

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/261020 A1

(51) International Patent Classification:

A61K 31/216 (2006.01) A61P 21/00 (2006.01)
A61K 31/41 (2006.01) A61P 21/04 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2024/067027

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(22) International Filing Date:

19 June 2024 (19.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23180395.8 20 June 2023 (20.06.2023) EP
24157608.1 14 February 2024 (14.02.2024) EP

(71) Applicant: NMD PHARMA A/S [DK/DK]; Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK).

(72) Inventors: PETERSEN, Thomas Kongstad; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK). KELLY, Nicholas Michael; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK). PEDERSEN, Thomas Holm; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK). SAMPSON, Claire, Margaret; C/O NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N (DK).

(74) Agent: HØIBERG P/S; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES

(57) Abstract: The present disclosure relates to compounds capable of inhibiting the CLC-1 ion channel for use in treating, ameliorating and/or preventing multiple sclerosis and other neuromuscular diseases.

WO 2024/261020 A1